Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report

Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report

Abstract Background Hypereosinophilic syndrome is a group of disorders characterized by organ dysfunction caused by hypereosinophilia, which frequently leads to thromboembolic complications with potentially fatal outcomes. Interleukin-5, a key cytokine that promotes the differentiation and activatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Daiki Nagira, Satoshi Miyamoto, Taishiro Mizukoshi, Atsushi Yanagisawa, Atsushi Funauchi, Kensuke Kanaoka, Hanako Yoshimura, Tatsunori Jo, Masayoshi Higashiguchi, Yujiro Naito, Takayuki Shiroyama, Satoshi Tetsumoto, Haruhiko Hirata, Yoshito Takeda, Atsushi Kumanogoh
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Hypereosinophilic syndrome (HES)
Thromboembolism
Anticoagulant therapy
Steroid
Interleukin-5 receptor (IL-5 receptor)
Benralizumab
Online Access:https://doi.org/10.1186/s13223-025-00967-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13223-025-00967-2

Similar Items